Aptose Biosciences INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Aptose Biosciences announced positive safety, response, and MRD data from its TUSCANY Phase 1/2 trial of tuspetinib triplet therapy in newly diagnosed AML patients at the 2026 EHA Congress.
Aptose Biosciences reports a delay in the closing of its acquisition by Hanmi Pharmaceutical due to pending Korean regulatory approvals, now targeting a June completion.
Aptose Biosciences reports Q1 2026 financial results while awaiting regulatory approval for its acquisition by Hanmi Pharmaceutical.
Aptose Biosciences announced a delay in the closing of its acquisition by Hanmi Pharmaceutical due to pending Korean regulatory approvals, now targeting May for completion.
Aptose Biosciences shareholders approved its acquisition by Hanmi Pharmaceutical, with the company also reporting its year-end 2025 financial results and positive clinical data for its AML therapy.
Aptose Biosciences shareholders overwhelmingly approved the plan of arrangement for acquisition by Hanmi Pharmaceutical and a corporate continuance to Alberta.
Aptose Biosciences Inc. amended its CEO's employment agreement to clarify deferred compensation and tax responsibilities.
Leading independent proxy advisory firm Glass Lewis recommends Aptose shareholders vote FOR the proposed Plan of Arrangement with Hanmi Pharmaceutical.
Independent proxy advisory firm ISS recommends Aptose Biosciences shareholders vote FOR the proposed acquisition by Hanmi Pharmaceutical.
Aptose Biosciences Inc. has amended its arrangement agreement with Hanmi Pharmaceutical, postponing its shareholder meeting to March 31, 2026, and securing an additional US$11.1 million uncommitted facility to advance Tuspetinib development.
Aptose Biosciences has rescheduled its special shareholder meeting to approve the acquisition by Hanmi Pharmaceutical Co. Ltd., pending final SEC proxy statement clearance.
Aptose Biosciences announced promising clinical data for its tuspetinib triple drug therapy, demonstrating high response rates and safety in newly diagnosed AML patients at the 2025 ASH Annual Meeting.
Aptose Biosciences Inc. has entered into a definitive arrangement agreement to be acquired by Hanmi Pharmaceuticals Co. Ltd. and its subsidiary HS North America Ltd. for C$2.41 per common share in cash.
Aptose Biosciences will be acquired by Hanmi Pharmaceutical for C$2.41 per share in cash, representing a 28% premium, to advance the TUSCANY clinical study.
Aptose Biosciences reported strong clinical trial results for its AML drug tuspetinib, showing 100% complete responses at higher doses, despite significant cash flow challenges.
Aptose Biosciences announced its TUSCANY study data for tuspetinib in newly diagnosed AML will be presented at the 2025 ASH Annual Meeting.
Aptose Biosciences' tuspetinib, combined with standard care, achieved 100% complete remission rates in newly diagnosed AML patients at higher doses, surpassing expectations.
Aptose Biosciences extended its loan agreement with Hanmi Pharmaceutical for $11.9 million to advance its AML drug tuspetinib, citing positive clinical data.
Aptose Biosciences Inc. has appointed Ernst & Young LLP as its new independent registered public accounting firm, replacing KPMG LLP, following shareholder approval.
Aptose Biosciences Inc. has granted cash retention awards to its CEO, CFO, and CMO, payable upon a Change of Control.
Aptose Biosciences announced the appointment of Ernst & Young LLP as its new auditor and received an additional US$1.5 million advance from Hanmi Pharmaceutical for tuspetinib development.
Aptose Biosciences announced the appointment of Ernst & Young as its new auditor and received an additional US$1.5 million advance from Hanmi Pharmaceutical for tuspetinib development.
Aptose Biosciences reported positive early data from its Phase 1/2 TUSCANY trial, showing high response and MRD-negativity rates for its tuspetinib-based triplet therapy in newly diagnosed AML patients.
Aptose Biosciences reported Q2 2025 results, highlighting positive clinical trial data for tuspetinib in AML with dose escalation, alongside significant cash flow challenges and reliance on a new loan facility.
Aptose Biosciences' TUSCANY trial for AML advances to a 160 mg tuspetinib dose cohort after positive safety and efficacy data, securing additional funding.
Aptose Biosciences Inc. announced receipt of a US$2.0 million advance from Hanmi Pharmaceutical, bringing total advances to US$4.5 million under an US$8.5 million loan agreement, to further develop its tuspetinib-based triplet therapy for acute myeloid leukemia.
Aptose Biosciences Inc. has entered into an agreement with Hanmi Pharmaceutical Co., Ltd. to defer interest payments until December 31, 2025, as it plans to raise $15 million through various offerings.
Aptose Biosciences Inc. announced its upgrade to trade on the OTCQB Market under the ticker APTOF, effective July 1, 2025, alongside its continued listing on the Toronto Stock Exchange.
Aptose Biosciences Inc. has entered into an uncommitted loan agreement for up to US$8.5 million with Hanmi Pharmaceutical Co. Ltd. to fund the continued clinical development of its Tuspetinib (TUS) triple drug frontline therapy for acute myeloid leukemia (AML) and related business operations.
Aptose Biosciences Inc. announced a new uncommitted loan agreement for up to US$8.5 million with Hanmi Pharmaceutical Co. Ltd. to fund the continued clinical development of its lead drug candidate, tuspetinib, for acute myeloid leukemia.